Table 4Summary of findings table of effects of monoclonal antibodies in individuals exposed to SARS-CoV-2 (prophylaxis).
Outcomes Anticipated absolute effects* (95% CI) Relative effect
(95% CI)		 № of participants
(studies)		 Certainty of the evidence
(GRADE)
Risk with placebo Risk with Monoclonal antibodies
Symptomatic COVID-19
assessed with: positive PCR test plus COVID-19 symptoms
follow-up: median 28 days		 7 per 100 5 per 100
(2 to 10)		 RR 0.75
(0.36 to 1.54)		 2471
(2 RCTs)		 ⨁◯◯◯
Very lowa,b,c
Symptomatic and asymptomatic COVID-19
assessed with: Positive PCR test with or without COVID-19 symptoms
follow-up: median 28 days		 18 per 100 9 per 100
(4 to 21)		 RR 0.52
(0.23 to 1.17)		 2471
(2 RCTs)		 ⨁◯◯◯
Very lowa,d,e
All-cause mortality
follow-up: median 28 days		 1 per 100 1 per 100
(0 to 3)		 RR 0.83
(0.25 to 2.70)		 966
(1 RCT)		 ⨁⨁◯◯
Lowf
COVID-19 related death
follow-up: median 28 days		 1 per 100 0 per 100
(0 to 2)		 RR 0.11
(0.01 to 2.05)		 966
(1 RCT)		 ⨁⨁◯◯
Lowg
Viral load reduction from baseline
assessed with: log10
follow-up: median 28 days		 The mean viral load reduction from baseline was -0.39 log10 MD 0.8 log10 lower
(1.21 lower to 0.39 lower)		 - 132
(1 RCT)		 ⨁⨁⨁◯
Moderateh
Any adverse events
follow-up: median 28 days		 26 per 100 22 per 100
(14 to 33)		 RR 0.85
(0.56 to 1.28)		 3792
(2 RCTs)		 ⨁◯◯◯
Very lowa,i
Serious adverse events
follow-up: median 28 days		 2 per 100 2 per 100
(1 to 3)		 RR 0.93
(0.55 to 1.58)		 3792
(2 RCTs)		 ⨁⨁⨁◯
Moderatea
Bacteremia
follow-up: median 28 days		 2 per 100 1 per 100
(1 to 2)		 RR 0.70
(0.37 to 1.33)		 2680
(2 RCTs)		 ⨁⨁⨁◯
Moderatea
Explanations
a . RoB: O'Brien et al. at high risk of bias due to measurement of the outcome and selection of the reported result.
b . Inconsistency: I2=60%
c . Imprecision: 95%CI 0.36 to 1.54
d . Inconsistency: I2=93%
e . Imprecision: 95%CI 0.23 to 1.17
f . Imprecision: 95%CI 0.25 to 2.70
g . Imprecision: 95%CI 0.01 to 2.05
h . Imprecision: 95%CI -1.21 to -0.39 log10
i . Inconsistency: I2=89%